CareDx (CDNA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.37
- Estimate
- $0.23
- Surprise
- +59.5%
- Revenue (period 2026-06-30)
- $131.9M
- Score at report (before → after)
- 6.0 → 5.9/10
Revenue source: xbrl.
How the report landed
CareDx (CDNA) beat the $0.23 estimate with adjusted EPS of $0.37 — a large 59.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.0/10) to Hold at 5.9/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CDNA Hold at 6.3/10.
3 of the last 4 quarters beat the estimate; this quarter's +59.5% surprise compares with a +67.9% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.1 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: AlloSure/AlloMap/HeartCare transplant tests
- Analyst target reached - limited upside remaining
- Expensive valuation
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $63.79
- Price target
- $71.06
- Stop
- $59.32
- Upside to target
- +11.4%
Forward estimates sit below the trailing run-rate (49.4× forward vs 30.7× trailing) — consensus expects earnings to decline from here.
Risk check: trading volume is running 1.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
CDNA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $3.30B
- P/E (fwd)
- 49.4
- P/E (ttm)
- 30.7
- 52-week range
- $13.95–$72.51
- Off 52-week high
- 12.0%
- RSI (14)
- 68
- Volume vs avg
- 1.76×
- Score today
- 6.3/10